Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for Apathy in Alzheimer's Dementia
NCT01117181Phase 2Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Jun 2010
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in apathy (2 arms), sponsored by Johns Hopkins Bloomberg School of Public Health. Primary endpoints: Apathy Evaluation Scale at 6 weeks and Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change at 6 weeks. Started Jun 2010; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
apathy
Beyond the preview
Go deeper on NCT01117181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01117181.